[CITIC Construction Investment: AIDD companies are generally in an early stage and the industry is expected to enter an accelerated growth period] On October 3, CITIC Construction Investment released a research report stating that AIDD companies are generally in an early stage and the industry is expected to enter an accelerated growth period. AI biotech mainly includes three business models. The first is SAAS companies that only provide software services. The second is service CRO companies that use AI platforms to screen or evaluate new drugs for customers. Finally, there are AI innovative pharmaceutical companies that use AI platforms to independently design new drugs and promote pipelines. At present, most companies are in the early stages of development and adopt a combination of several business models. The overall AI pharmaceutical market is still relatively small. However, with the participation of more capital, technological changes, and the gradual launch of AI pharmaceutical pipelines and verification, the industry is expected to gradually usher in a harvest period.